CK-2127107

Research use only, not for human use.

CK-2127107(CK-107, Reldesemtiv)?is a novel orally active fast skeletal troponin activator, selectively activates fast skeletal myofibrils with EC50 of 3.4 uM.

CK-2127107(CK-107, Reldesemtiv)?is a novel orally active fast skeletal troponin activator, selectively activates fast skeletal myofibrils with EC50 of 3.4 uM; has no effect on slow skeletal or cardiac myofibrils; significantly improves rotarod performance in exercise-intolerant LAD-HF rats.Spinal Muscular Atrophy (SMA) Phase 2 Clinical.

——

Animal Model:Female Sprague-Dawley rats (Sham and left anterior descending coronary artery (LAD) heart failure (LAD-HF)) Dosage:10 mg/kg Administration:p.o.Result:Increased performance time by approximately 150% in LAD-HF rats (116±22 versus 283±47 seconds).

CK-107 | Reldesemtiv

Others

Other Targets

Other Targets

Neurological Disease

Spinal Muscular Atrophy(SMA)

1345410-31-2

384.391

C19H18F2N6O

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (650.40 mM)

O=C(C1=CN(C2=CN=C(NC[C@]3(C4=NC=CC=C4F)C[C@H](F)C3)N=C2)C=C1)N

1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide

(-20℃)

With Ice Pack

≥ 2 years